GB201417456D0 - Treatment of cancer - Google Patents

Treatment of cancer

Info

Publication number: GB201417456D0
Authority: GB; United Kingdom
Prior art keywords: cancer; treatment
Prior art date: 2014-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1417456.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Karo Healthcare AB

Original Assignee

Karo Bio AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-02

Filing date

2014-10-02

Publication date

2014-11-19

2014-10-02 Application filed by Karo Bio AB filed Critical Karo Bio AB

2014-10-02 Priority to GBGB1417456.9A priority Critical patent/GB201417456D0/en

2014-11-19 Publication of GB201417456D0 publication Critical patent/GB201417456D0/en

2015-10-01 Priority to PCT/EP2015/072763 priority patent/WO2016050945A1/en

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB1417456.9A 2014-10-02 2014-10-02 Treatment of cancer Ceased GB201417456D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1417456.9A GB201417456D0 (en)	2014-10-02	2014-10-02	Treatment of cancer
PCT/EP2015/072763 WO2016050945A1 (en)	2014-10-02	2015-10-01	Pharmaceutical combinations comprising estrogen receptor-beta agonists with platinum drugs or paclitaxel for treating ovarian cancer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1417456.9A GB201417456D0 (en)	2014-10-02	2014-10-02	Treatment of cancer

Publications (1)

Publication Number	Publication Date
GB201417456D0 true GB201417456D0 (en)	2014-11-19

Family

ID=51946756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1417456.9A Ceased GB201417456D0 (en)	2014-10-02	2014-10-02	Treatment of cancer

Country Status (2)

Country	Link
GB (1)	GB201417456D0 (en)
WO (1)	WO2016050945A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114249680B (en) *	2022-01-10	2022-12-27	深圳市乐土生物医药有限公司	Indole derivatives, and synthesis method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8377918B2 (en) *	2005-01-31	2013-02-19	ACC Therapeutics Inc	Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents
HUE025471T2 (en) *	2008-04-16	2016-03-29	Karobio Ab	Novel estrogen receptor ligands

2014
- 2014-10-02 GB GBGB1417456.9A patent/GB201417456D0/en not_active Ceased
2015
- 2015-10-01 WO PCT/EP2015/072763 patent/WO2016050945A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2016050945A1 (en)	2016-04-07

Publication	Publication Date	Title
IL250677A0 (en)	2017-03-30	Treatment of cancers using anti-nkg2a agents
PL3851537T3 (en)	2024-09-16	Treatment of hyperbilirubinemia
GB201701673D0 (en)	2017-03-15	Methods of well treatment
IL261959A (en)	2018-10-31	Treatment of cancer with tg02
LT3122358T (en)	2021-04-12	Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL285077A (en)	2021-08-31	Compounds for treatment of cancer
SG10201801562PA (en)	2018-04-27	Combination method for treatment of cancer
LT3622953T (en)	2021-04-26	Combination treatment of cancer
IL247859A0 (en)	2016-11-30	Cancer treatment
IL263835A (en)	2019-02-03	Exosome-guided treatment of cancer
GB201416832D0 (en)	2014-11-05	Methods of treatment
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201409363D0 (en)	2014-07-09	Skin cancer treatment
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201407837D0 (en)	2014-06-18	Methods of cancer therapy
ZA201704589B (en)	2019-02-27	Compounds for the treatment of cancer
GB201417456D0 (en)	2014-11-19	Treatment of cancer
GB201409362D0 (en)	2014-07-09	Treatment of cancer
GB201405449D0 (en)	2014-05-07	Treatment of cancer
GB201405075D0 (en)	2014-05-07	Treatment of cancer
GB201622214D0 (en)	2017-02-08	treatment of cancer
GB201512723D0 (en)	2015-08-26	Treatment of cancer
GB201507928D0 (en)	2015-06-24	Treatment of cancer
GB201504617D0 (en)	2015-05-06	Treatment of cancer
GB201417465D0 (en)	2014-11-19	Treatment of cancers

Legal Events

Date	Code	Title	Description
2016-07-20	AT	Applications terminated before publication under section 16(1)